CVRx (CVRX) AI Stock Analysis

• Market Cap: $224.22M
• Dividend Yield: N/A
• Average Volume (3M): 236.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 25.62%
• EPS Growth: 11.86%
• Country: US
• Employees: 206
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.53
• Shares Outstanding: 26,072,600
• 10 Day Avg. Volume: 365,720
• 30 Day Avg. Volume: 236,200
• PEG Ratio: -0.19
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.52
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 0.68
• Enterprise Value/Gross Profit: 3.00
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $10.75
• Price Target Upside: 31.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 59 Neutral
• Price Target: $9.00 ▲(9.89%Upside)

The overall stock score for CVRx is influenced primarily by its strong revenue growth and bullish technical indicators. However, significant challenges in profitability, cash flow management, and valuation are notable risks. The earnings call suggests optimism regarding long-term strategies, yet immediate concerns remain.

Positive Factors

Growth Outlook

Rep productivity increases, more predictable reimbursement on the horizon, and focus on top-tier accounts could return the company back to its prior longer-term growth outlook.

Reimbursement

Maintaining Barostim’s current reimbursement under New Tech APC 1580 should be considered a win for CVRX.

Salesforce

Management is 'thrilled' with the experience of new reps onboarding, the majority of whom have experience in therapy development, stakeholder relationships from their prior company, and an understanding of cardiac medicine.

Negative Factors

Salesforce Disruption

The Q1 miss was attributed to the company being unable to manage the disruption from the deeper-than-expected salesforce changes.

Turnover

Greater seasonality than expected and increased turnover that was over 90% company initiated impacted results.

CVRx Business Overview & Revenue Model

Company Description

CVRx, Inc. is a medical device company that operates within the healthcare sector, focusing on the development and commercialization of innovative neuromodulation solutions. Its core product, the Barostim System, is designed to improve the quality of life for patients with cardiovascular diseases such as heart failure and hypertension by using the body's natural feedback mechanisms.

How the Company Makes Money

CVRx generates revenue primarily through the sale of its Barostim System to hospitals and healthcare providers. The company may also engage in partnerships with healthcare institutions and organizations to facilitate the adoption and integration of its technology into clinical practice. Additionally, CVRx may receive revenue from service agreements related to the installation, training, and maintenance of its devices. The company's earnings are influenced by factors such as the adoption rate of its technology, market penetration, and reimbursement policies from insurance providers.

CVRx Financial Statement Overview

Summary

CVRx demonstrates robust revenue growth but faces significant challenges in profitability and cash flow management. The balance sheet is stable with manageable debt, yet negative returns on equity indicate a need for operational improvements.

Income Statement

CVRx shows a strong revenue growth with a 34.6% increase from 2023 to TTM (Trailing-Twelve-Months). However, the company is facing significant net losses with a negative net profit margin of -97.5% in TTM, indicating challenges in achieving profitability. The negative EBIT and EBITDA margins further highlight operational inefficiencies.

Balance Sheet

The company's equity ratio stands at 53.5% in TTM, indicating a moderate level of equity financing. However, the debt-to-equity ratio is 0.72, suggesting a manageable level of debt. The negative net income leads to a negative ROE, signaling challenges in generating shareholder returns.

Cash Flow

CVRx shows a negative free cash flow, albeit with a slight improvement in free cash flow growth from the previous period. The operating cash flow to net income ratio is negative, reflecting ongoing cash flow constraints. The company has a healthy cash position from financing activities, providing liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.29M	39.30M	22.47M	13.04M	6.05M
Gross Profit	42.96M	33.04M	17.47M	9.40M	4.61M
EBITDA	-54.89M	-38.73M	-40.74M	-40.60M	-11.48M
Net Income	-59.97M	-41.20M	-41.43M	-43.08M	-14.11M
Balance Sheet
Total Assets	133.41M	115.23M	124.94M	152.55M	64.78M
Cash, Cash Equivalents and Short-Term Investments	105.93M	90.57M	106.19M	142.07M	59.11M
Total Debt	50.43M	30.61M	7.09M	0.00	19.28M
Total Liabilities	62.36M	39.28M	15.76M	6.59M	358.01M
Stockholders Equity	71.06M	75.95M	109.18M	145.96M	-293.24M
Cash Flow
Free Cash Flow	-40.51M	-39.61M	-43.36M	-28.91M	-16.41M
Operating Cash Flow	-39.14M	-39.02M	-42.68M	-27.73M	-16.10M
Investing Cash Flow	-1.36M	-591.00K	-685.00K	-1.18M	-311.00K
Financing Cash Flow	55.87M	23.98M	7.49M	111.88M	49.78M

CVRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Positive. The current price of 8.19 is above the 20-day moving average (MA) of 7.16, above the 50-day MA of 6.64, and below the 200-day MA of 10.82, indicating a neutral trend. The MACD of 0.53 indicates Negative momentum. The RSI at 61.95 is Neutral, neither overbought nor oversold. The STOCH value of 73.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVRX.

CVRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	73 Outperform	$228.67M	54.89	7.41%	―	26.86%	―
CVRX	59 Neutral	$224.22M	―	-76.01%	―	25.62%	11.86%
MASS	59 Neutral	$264.66M	―	-44.97%	―	21.06%	-99.70%
MYO	53 Neutral	$77.71M	―	-35.68%	―	69.17%	39.01%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
LNSR	47 Neutral	$156.67M	―	-304.05%	―	28.24%	-334.39%
TLSI	47 Neutral	$178.49M	―	271.41%	―	85.03%	53.73%

CVRx Corporate Events

CVRx Confirms Directors and Accounting Firm at Meeting

On June 3, 2025, CVRx, Inc. held its annual meeting of stockholders where key decisions were made. The election of two Class I directors, Kevin Ballinger and Mitch Hill, was confirmed, and the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are pivotal for CVRx’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (CVRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.